It is currently Sun Oct 22, 2017 2:04 pm



All times are UTC - 5 hours [ DST ]


Our Sponsors





Post new topic Reply to topic  [ 3 posts ] 
Author Message
PostPosted: Wed Apr 05, 2017 2:04 am 
Offline
Long Time Member
Long Time Member
User avatar

Joined: Sat Aug 04, 2012 11:02 pm
Posts: 1016
Not related to Suboxone, but still a curious look as to RB's business practices:

http://www.theage.com.au/business/consumer-affairs/nurofen-must-pay-6-million-penalty-after-final-appeal-rejected-20170405-gve15i.html

Quote:
The company that manufactures Nurofen must pay a $6 million penalty it was handed for misleading consumers with its specific pain relief range, after a final appeal to the High Court was rejected on Wednesday.

The $6 million corporate penalty, the highest ever awarded for misleading conduct under the Australian Consumer Law, was issued by the Full Federal Court in December last year.

Following that decision, pharmaceutical company Reckitt Benckiser applied for special leave to appeal to the High Court of Australia on a number of grounds, including that the Full Court had erred in its assessment of consumer loss and in finding that the original penalty was manifestly inadequate.

The $6 million penalty was a revised figure, up from an initial penalty of $1.7 million, which was appealed by the Australian Competition and Consumer Commission for being an insufficient "deterrent" to a company of its size.

The ACCC took Reckitt Benckiser to the Federal Court over allegations the company had engaged in misleading or deceptive conduct by claiming that Nurofen Specific Pain products were formulated to specifically treat a particular type of pain, when this was not the case.

Rather, each Nurofen Specific Pain product contains the same active ingredient, ibuprofen lysine 342mg, which is used to treat a variety of pain conditions and is no more effective at a specific pain-type than any other Nurofen Specific Pain products.

ACCC chairman Rod Sims described the $6 million penalty in December as "a great win for Australian consumers".

"We are running a campaign to end misleading conduct by large companies. We think this helps send that message," Mr Sims told Fairfax Media.

He said the penalty reflected the widespread nature of the conduct and the substantial sales and profit that were made.

It is estimated that 5.9 million sales of the four products over five years yielded revenue of about $45 million to the pharmaceutical company.

A Nurofen spokeswoman said it was disappointed by the High Court's decision on Wednesday, as it considered the application raised serious questions on whether the Full Court's reasoning and amended penalty was correct in all of the circumstances.

"In 2015, Nurofen accepted that the representations made on the Nurofen Specific Pain Range webpage and packaging may have misled consumers...Nurofen did not intend to mislead consumers and we apologise to those of our consumers who were misled," she said.

"The Nurofen Specific Pain Range was introduced with the intention to provide easy navigation of pain relief options, particularly within the grocery environment where pharmacy support is not available."

In accordance with the court penalty order, Reckitt Benckiser paid the required $6 million in January, within 30 days of the penalty being issued.


Top
 Profile  
 
PostPosted: Wed Apr 05, 2017 5:43 am 
Offline
Moderator
Moderator

Joined: Fri May 01, 2015 9:58 am
Posts: 889
Hi TeeJay, Very interesting! Thanks for sharing!


Top
 Profile  
 
PostPosted: Wed Apr 05, 2017 2:17 pm 
Offline
Moderator
Moderator
User avatar

Joined: Thu Feb 23, 2012 4:42 am
Posts: 4255
Ha ha! I didn't have a major problem with RB until they wrote the completely disingenuous Citizens Petition to the FDA in a bid to keep their expiring patent from becoming available to other pharmaceutical manufacturers for generic production.

Their duplicitous bid was DENIED by the FDA, who saw through the charade. You can find the fascinating story in a blog post by Dr. J here:

http://suboxonetalkzone.com/suboxone-ma ... ed-by-fda/

Enjoy!

Amy

_________________
Done is better than perfect!


Top
 Profile  
 
Display posts from previous:  Sort by  
Post new topic Reply to topic  [ 3 posts ] 

All times are UTC - 5 hours [ DST ]


Who is online

Users browsing this forum: No registered users and 1 guest


You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot post attachments in this forum

Search for:
Jump to:  
Our Sponsors
Suboxone Forum latest topics RSS feed Subscribe to the entire forum
 

 

 
Fond Du Lac Psychiatry
Dr. Jeffrey Junig, M.D., Ph.D.

  • Board Certified Psychiatrist
  • Asst Clinical Professor, Medical College of Wisconsin

Powered by phpBB® Forum Software © phpBB Group